Roche Holding AG (RHHBY) Virtual Hematology Investor Conference Transcript

Group 1 - Roche Holding AG is hosting its fifth Investor Relations call of the year, focusing on the latest clinical results from its hematology portfolio, including both malignant and non-malignant conditions [3][4] - The call will feature a presentation by Charles Fuchs, the Global Head of Oncology and Hematology Product Development, who will discuss the latest data on Non-Hodgkin Lymphoma (NHL), particularly the Phase III SUNMO results for Lunsumio plus Polivy in second-line DLBCL [5]